Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 8/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | EDNRA | P25101 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.35 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.34 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL9487151 | 1.00 | EPHX1 (0.60) | EPHX1TSHRMEN1TP53CYP1A2 | |
| Potassium Ion SCHEMBL4885554 | 1.00 | EPHX1 (0.60) | EPHX1TSHRMEN1TP53CYP1A2 | |
| Potassium Ion SCHEMBL9487155 | 1.00 | EPHX1 (0.60) | EPHX1TSHRMEN1TP53CYP1A2 | |
| SCHEMBL6027430 | 0.96 | EPHX1 (0.60) | EPHX1TSHRMEN1TP53CYP1A2 | |
| Lithium Ion SCHEMBL10477590 | 0.96 | EPHX1 (0.60) | EPHX1TSHRMEN1TP53CYP1A2 | |
| SCHEMBL9459180 | 0.96 | EPHX1 (0.60) | EPHX1TSHRMEN1TP53CYP1A2 | |
| Potassium Ion SCHEMBL28558054 | 0.82 | EPHX1 (0.60) | EPHX1TSHRMEN1TP53CYP1A2 | |
| Potassium Ion SCHEMBL28556849 | 0.82 | EPHX1 (0.42) | EPHX1TSHRMEN1TP53CYP1A2 | |
| SCHEMBL15307543 | 0.80 | EPHX1 (0.67) | EPHX1TSHRMEN1TP53CYP1A2 | |
| SCHEMBL9458781 | 0.80 | EPHX1 (0.67) | EPHX1TSHRMEN1TP53CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1412319-A1 | CHIRAL RESOLUTION METHOD FOR PRODUCING COMPOUNDS USEFUL IN THE SYNTHESIS OF TAXANES | NAPRO BIOTHERAPEUTICS, INC. (US) | 2004-04-28 | — | — | EP | disclosed |
| US-6653501-B2 | Using chromatographic process for separating a target chiral compound from its enantiomer in a racemic mixtures; purification | NAPRO BIOTHERAPEUTICS, INC. | 2003-11-25 | — | — | US | disclosed |
| US-20030045743-A1 | Chiral resolution method for producing compounds useful in the synthesis of taxanes | MAYNE PHARMA (USA), INC. | 2003-03-06 | — | — | US | disclosed |
| WO-2003002509-A1 | CHIRAL RESOLUTION METHOD FOR PRODUCING COMPOUNDS USEFUL IN THE SYNTHESIS OF TAXANES | NAPRO BIOTHERAPEUTICS, INC. (US) | 2003-01-09 | — | — | WO | disclosed |
| US-5256803-A | Process for the preparation of (2R,3R)-cis)-β-phenylglycidic acid | RHONE-POULENC RORER S.A. (FR) | 1993-10-26 | — | — | US | disclosed |
| EP-0157327-B1 | NOVEL COMPOUNDS FOR DETECTING THE PRESENCE OF HYDROLYTIC ANALYTES IN A TEST SAMPLE | MILES INC. (US) | 1991-06-12 | — | — | EP | disclosed |
| EP-0158204-B1 | COMPOSITION AND TEST DEVICE FOR DETERMINING THE PRESENCE OF LEUKOCYTES, CONTAINING A ZWITTERION COUPLING AGENT | MILES INC. (US) | 1989-11-23 | — | — | EP | disclosed |
| EP-0157326-B1 | COMPOSITION AND TEST DEVICE FOR DETERMINING THE PRESENCE OF LEUKOCYTES, ESTERASE AND PROTEASE IN A TEST SAMPLE | MILES INC. (US) | 1989-05-31 | — | — | EP | disclosed |
| US-4774340-A | AMINATION, CYCLIZATION, ESTERIFICATION | MILES INC. (US) | 1988-09-27 | — | — | US | disclosed |
| US-4716236-A | Method for synthesizing esters | MILES LABORATORIES, INC. (US) | 1987-12-29 | — | — | US | disclosed |
| US-4704460-A | LEUKOCYTES IN URINE | MILES LABORATORIES, INC. (US) | 1987-11-03 | — | — | US | disclosed |
| US-4657855-A | DIP-AND-READ, UROGENITAL DISORDERS | MILES LABORATORIES, INC. (US) | 1987-04-14 | — | — | US | disclosed |
| US-4645842-A | DETECTING LEUKOCYTES TO INDICATE KIDNEY OR UROGENITAL DISORDERS | MILES LABORATORIES, INC. (US) | 1987-02-24 | — | — | US | disclosed |
| US-4637979-A | Composition and test device for determining the presence of leukocytes containing a zwitterion coupling agent | MILES LABORATORIES, INC. (US) | 1987-01-20 | — | — | US | disclosed |
| EP-0158204-A2 | Composition and test device for determining the presence of leukocytes, containing a zwitterion coupling agent | MILES INC. (US) | 1985-10-16 | — | — | EP | disclosed |
| EP-0158226-A2 | Method of synthesizing esters | MILES INC. (US) | 1985-10-16 | — | — | EP | disclosed |
| EP-0157327-A2 | Novel compounds for detecting the presence of hydrolytic analytes in a test sample | MILES INC. (US) | 1985-10-09 | — | — | EP | disclosed |
| EP-0157326-A2 | Composition and test device for determining the presence of leukocytes, esterase and protease in a test sample | MILES INC. (US) | 1985-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045743-A1 | Chiral resolution method for producing compounds useful in the synthesis of taxanes | CCNK, OPRK1, SYMPK | EPHX1 1034/4885TSHR 3694/4885MEN1 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.